Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial

Christian Kromer, Viktoria P Nühnen, Wolfgang Pfützner, Sebastian Pfeiffer, Hans-Joachim Laubach, Wolf-Henning Boehncke, Joerg Liebmann, Matthias Born, Michael P Schön, Timo Buhl, Christian Kromer, Viktoria P Nühnen, Wolfgang Pfützner, Sebastian Pfeiffer, Hans-Joachim Laubach, Wolf-Henning Boehncke, Joerg Liebmann, Matthias Born, Michael P Schön, Timo Buhl

Abstract

Background: Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.

Objective: We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.

Methods: We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).

Results: The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).

Conclusions: We will disseminate the results in a peer-reviewed journal.

Trial registration: ClinicalTrials.gov NCT03085303; https://ichgcp.net/clinical-trials-registry/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).

International registered report identifier (irrid): DERR1-10.2196/11911.

Keywords: atopic dermatitis; atopic eczema; blue light; irradiation; ultraviolet light.

Conflict of interest statement

Conflicts of Interest: MB and JL are employees of Philips Light & Health.

©Christian Kromer, Viktoria P Nühnen, Wolfgang Pfützner, Sebastian Pfeiffer, Hans-Joachim Laubach, Wolf-Henning Boehncke, Joerg Liebmann, Matthias Born, Michael P Schön, Timo Buhl. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 08.01.2019.

Figures

Figure 1
Figure 1
Design of the FBB-CT01 device (415 nm and 450 nm). The patient lies on the treatment table and receives treatment from the light engine above.

References

    1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X.
    1. Irvine AD, McLean WHI, Leung DYM. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011 Oct 06;365(14):1315–27. doi: 10.1056/NEJMra1011040.
    1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11–8.
    1. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–9. doi: 10.1159/000245677.
    1. Stalder J, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taïeb A, PO-SCORAD Investigators Group Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011 Aug;66(8):1114–21. doi: 10.1111/j.1398-9995.2011.02577.x.
    1. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016 Feb;74(2):288–94. doi: 10.1016/j.jaad.2015.09.062.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–6.
    1. Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Gieler U, Kahle J, Kapp A, Nast A, Nemat K, Ott H, Przybilla B, Roecken M, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Worm M. S2k guideline on diagnosis and treatment of atopic dermatitis--short version. J Dtsch Dermatol Ges. 2016 Jan;14(1):92–106. doi: 10.1111/ddg.12871.
    1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191.
    1. Becker D, Langer E, Seemann M, Seemann G, Fell I, Saloga J, Grabbe S, von Stebut E. Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS One. 2011;6(6):e20566. doi: 10.1371/journal.pone.0020566.
    1. Keemss K, Pfaff SC, Born M, Liebmann J, Merk HF, von Felbert V. Prospective, Randomized Study on the Efficacy and Safety of Local UV-Free Blue Light Treatment of Eczema. Dermatology. 2016;232(4):496–502. doi: 10.1159/000448000.
    1. Pfaff S, Liebmann J, Born M, Merk HF, von Felbert V. Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris. Dermatology. 2015;231(1):24–34. doi: 10.1159/000430495.
    1. Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology. 2011;223(3):251–9. doi: 10.1159/000333364.
    1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338–51. doi: 10.1016/j.jaad.2013.10.010.
    1. General Assembly of the World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81(3):14–8.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅